Equine EGF (Epidermal Growth Factor) is a growth factor peptide belonging to the EGF family of ligands, which also includes transforming growth factor-α (TGF-α), amphiregulin (AREG), heparin-binding EGF-like growth factor (HB-EGF), betacellulin (BTC), and epiregulin (EREG) that signal through the epidermal growth factor receptor (EGFR/ErbB1) to regulate cell proliferation, differentiation, and tissue repair. In horses (Equus caballus), EGF is produced by epithelial cells, fibroblasts, macrophages, and glandular tissues, including the salivary glands and gastrointestinal epithelium, where it supports maintenance and regeneration of epithelial tissues such as the skin, cornea, and intestinal lining. Binding of EGF to EGFR activates intracellular signaling pathways including MAPK/ERK, PI3K–AKT, and JAK/STAT, promoting cell proliferation, survival, and tissue remodeling following injury or inflammation. In equine health, EGF contributes to cutaneous wound healing and mucosal repair, processes that are particularly relevant in horses due to their susceptibility to chronic or slow-healing skin wounds. Horses are also used as comparative animal models for musculoskeletal and skin repair, and EGF signaling has been studied in equine wound healing models, where EGFR-mediated pathways influence fibroblast activity, epithelial regeneration, and tissue remodeling, providing insights relevant to both veterinary medicine and human regenerative therapies.